Search
Tisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalTisotumab vedotin is a tissue factor-directed antibody-drug conjugate (ADC) comprised of an anti-tissue factor (TF) human IgG1-kappa antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting … [A238914] On September 20, 2021, the FDA granted accelerated approval to tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer in adults in whom the disease progressed during
Vemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigationalAfter approval, Roche in collaboration with Genentech launched a broad development program. [L1012] … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
go.drugbank.com/drugs/DB10991ApprovedInvestigationalBordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) is a vaccine that is used in the prophylaxis of Pertussis (whooping cough), which is caused by a small Gram-negative coccobacillus
Mixtures: Covaxis Injektionssuspension in einer FertigspritzeCategories: Complex MixturesBirch bark extract
go.drugbank.com/drugs/DB16536ApprovedInvestigational[L42380] Two oleogel formulations of birch bark extract (Oleogel-S10, 10% of triterpene dry extract in sunflower oil) have been approved by the European Medicines Agency. … [L42365,L42370] Filsuvez, one of these two formulations, is approved for the treatment of partial thickness wounds in patients with epidermolysis bullosa (EB), a rare group of hereditary disorders of the
Categories: Complex MixturesConcizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigational[L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors. … [A264883,A264878] In patients with hemophilia A or B - characterized by deficiencies in clotting factors VIII or IX, respectively - the traditional treatment involves replacement of the missing clotting
Lotilaner
go.drugbank.com/drugs/DB17992ApprovedInvestigationalVet approved[L47546] Lotilaner has largely been used for veterinary uses as an antiparasitic agent to treat flea and tick infestations in animals. … The active ingredient found in drug products of lotilaner is the S-enantiomer.
Synonyms: 2-thiophenecarboxamide, 5-((5s)-4,5-dihydro-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-3-isoxazolyl)-3-methyl-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-, 3-methyi-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-5-((55)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl)thiophene-2-carboxamideEzogabine
go.drugbank.com/drugs/DB04953ApprovedWithdrawnin adult patients with refractory epilepsy. … It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures
Synonyms: N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester, N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl esterFruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigationalThis approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase in overall survival rate was observed in both trials.[L48791] … -, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
Milsaperidone
go.drugbank.com/drugs/DB24348ApprovedInvestigationalMilsaperidone is an atypical antipsychotic agent that rapidly interconverts to [iloperidone] in vivo. … [L56056] On February 20, 2026, milsaperidone was approved by the FDA for the treatment of Bipolar I Disorder and schizophrenia.[L56059]
Propyliodone
go.drugbank.com/drugs/DB09366ApprovedRadiopaque medium usually in oil; used in bronchography.
Categories: Compounds used in a research, industrial, or household setting